Jeffrey S. Hackman - 09 Sep 2022 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role: Chairman, President and Chief Executive Officer. Exhibit 24 Power of Attorney filed herewith., Director
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol: CMRA on OTC
Transactions as of: 09 Sep 2022
Net transactions value: +$98,056
Form type: 4
Filing time: 12 Sep 2022, 17:23:31 UTC
Previous filing: 11 Aug 2022
Next filing: 16 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CMRA	Common Stock	Purchase	$98,056	+47,600		$2.06^*	47,600	09 Sep 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.10, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Remarks:

Chairman, President and Chief Executive Officer. Exhibit 24 Power of Attorney filed herewith.